Novo Nordisk’s obesity drug CagriSema’s test results showed an average weight loss of over 20%, but its stock slid in response to this news. The drug-maker’s own target was higher and market ...
Inquirer on MSN50m
US approves first-ever obstructive sleep apnea drugOn December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback